Here, we demonstrate that BUB1 inhibition sensitizes both NSCLC and SCLC to radiotherapy and chemoradiation, thus providing a rationale for designing clinical trials combining BUB1i with SOC therapies. This evidence concerns the gene BUB1 and non-small cell lung carcinoma.